Search

Due to its anti-angiogenic properties, trebananib is frequently employed in the treatment of cancer patients, particularly those with ovarian cancer. We conducted a meta-analysis to assess the efficacy and safety profile of trebananib in combination with other drugs for treating both ovarian and non-ovarian cancer patients. Our search encompassed PubMed, Medline, Cochrane, and Embase databases, with a focus on evaluating study quality. Data extraction was conducted from randomized controlled trials (RCTs), and RevMan 5.3 facilitated result analysis. Combining trebananib with other drugs extended progression-free survival (PFS) [HR 0.81, (95%CI: 0.65, 0.99), p = 0.04] and overall survival (OS) [HR 0.88, (95%CI: 0.79, 1.00), p = 0.04] in ovarian cancer patients. Ovarian cancer patients exhibited a higher objective response rate (ORR) with trebananib compared to non-ovarian cancer cohorts. Moreover, the incorporation of trebananib into the standard treatment regimen for malignant tumors did not significantly elevate drug-related adverse events [RR 1.05, (95% CI: 1.00, 1.11), p = 0.05]. Trebananib plus other drugs can improve the PFS, OS and ORR in patients with cancer, especially ovarian cancer. Our recommendation is to use trebananib plus other drugs to treat advanced cancer, and to continuously monitor and manage drug-related adverse events. PROSPERO (No. CRD42023466988) [ABSTRACT FROM AUTHOR]

BACKGROUND: Normal sagittal balance of cervical spine is the key to cervical spine orthopedic surgery. As the complexity of the anatomical structure and physiological function of the cervical spine, accurate measurement of sagittal balance parameters and correlation between parameters become an important reference for preoperative planning and postoperative evaluation of curative effect. Current research focuses on patients with clinical symptoms of cervical syondylosis. OBJECTIVE: To investigate the correlation of parameters of lordosis type cervical spine saggital plane in asymptomatic adults. METHODS: Cervical anteroposterior and lateral DR images of 120 adult patients with asymptomatic lordosis type cervical spine were retrospectively analyzed. The subjects were divided into three groups according to age: group A (21-40 years), group B (41-60 years), and group C (61-80 years). The sagittal parameters of the cervical spine were measured, including C2-C7 sagittal vertical axis (C2-C7 SVA), central of gravity to C7, sagittal vertical axis (CG-C7 SVA), T1 slope, C0-C2 Cobb angle and C2-C7 Cobb angle. The correlation between different imaging parameters and age was analyzed. This study was approved by the Ethics Committee, First Hospital of Shijiazhuang and Second Hospital of Hebei Medical University. All subjects signed the informed consent. RESULTS AND CONCLUSION: (1) C2-C7 SVA (F=11.188, P < 0.001), CG-C7 SVA (F=6.132, P=0.003) and T1 slope (F=11.682, P < 0.001) were significantly different among different groups. There was no significant difference in C0-C2 Cobb angle (F=1.178, P=0.311) and C2C7 Cobb angle (F=0.860, P=0.426)- (2) T1 slope was (51.63±5.85)°, (54.66±5.58)° and (57.48±4.74)° in groups A, Band C, respectively. Linear correlation analysis showed that T1 slope was positively correlated with age (r-0.533, P < 0.001 ). T1 slope was positively correlated with C2-C7 Cobb angle (r-0.561, P < 0.001). These results indicated that T1 slope increased with age in asymptomatic cervical lordosis adults. Moreover, T1 slope was positively correlated with age. [ABSTRACT FROM AUTHOR]

Defining radioiodine-refractory differentiated thyroid cancer: efficacy and safety of lenvatinib by radioiodine-refractory criteria in the SELECT trial. What's more, Nair's paper, published in 2015, was a summary of the FDA's approval of lenvatinib for radioiodine-resistant thyroid cancer treatment, and the data here were identical to those in the SELECT study. Keywords: lenvatinib; meta-analysis; radioiodine-refractory thyroid carcinoma; systematic review EN lenvatinib meta-analysis radioiodine-refractory thyroid carcinoma systematic review 275 276 2 01/03/23 20230201 NES 230201 We read with great interest the paper by Yan et al., sharing the perspective that lenvatinib is beneficial for the treatment of radioiodine-refractory thyroid cancer in terms of the extension of progression-free survival (PFS) and overall survival (OS).[1] We greatly appreciated the authors' contributions in studying the treatment of thyroid cancer refractory to radioactive iodine, however, it seems to be some critical problems when the authors drew to this conclusion. [Extracted from the article]